Journal Article

The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges

Amhaz, Ghid, Mukherji, Deborah, Chedid, Andrea, Temraz, Sally, Bouferraa, Youssef, El Lakkiss, Ahmed, Shamseddine, Ali

2021

Overview

The introduction of immune checkpoint inhibitors has constituted a major revolution in the treatment of patients with cancer. In contrast with the traditional cytotoxic therapies that directly kill tumor cells, this treatment modality enhances the ability of the host’s immune system to recognize and target cancerous cells. While immune checkpoint inhibitors have been effective across multiple cancer types, overcoming resistance remains a key area of ongoing research. The gut microbiota and its role in cancer immunosurveillance have recently become a major field of study. Gut microbiota has been shown to have direct and systemic effects on cancer pathogenesis and hosts anti-tumor immune response. Many studies have also shown that the host microbiota profile plays an essential role in the response to immunotherapy, especially immune checkpoint inhibitors. As such, modulating this microbial environment has offered a potential path to overcome the resistance to immune checkpoint inhibitors. In this review, we will talk about the role of microbiota in cancer pathogenesis and immune-system activity. We will also discuss preclinical and clinical studies that have increased our understanding about the roles and the mechanisms through which microbiota influences the response to treatment with immune checkpoint inhibitors.

• Publisher: MDPI AG,MDPI
• Subject: Antigens / Biomarkers / Colorectal cancer / Cytotoxicity / Dendritic cells / Gastric cancer / Gut microbiota / Immune checkpoint inhibitors / Immune response / Immune system / Immunotherapy / Inflammation / Microbiota / Mutation / Pathogenesis / Pattern recognition / Review / Sarcoma / Tumors